Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 21
- 试验地点
- 15
- 主要终点
- All-cause mortality of COVID-19 patients with liver cirrhosis
研究概览
简要总结
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
详细描述
Coronavirus disease 2019 (COVID-19) pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 or above;
- •Laboratory-confirmed COVID-19 infection;
- •Pre-existing liver cirrhosis based on liver biopsy or clinical findings.
排除标准
- •Pregnancy or unknown pregnancy status.
结局指标
主要结局
All-cause mortality of COVID-19 patients with liver cirrhosis
时间窗: From illness onset of COVID-19 to death from any cause, up to 365 days
7-day, 28-day, 60-day, 180-day and 365-day all-cause mortality of COVID-19 patients with liver cirrhosis
次要结局
- Liver-related mortality of COVID-19 patients with liver cirrhosis(From illness onset of COVID-19 to death from liver-related cause, up to 365 days)
- Baseline characteristics of COVID-19 patients with liver cirrhosis(1 Day)
- Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis(From hospital admission to death, up to 365 days)
研究者
Xiaolong Qi
Chief, Institute of Portal Hypertension
Hepatopancreatobiliary Surgery Institute of Gansu Province